cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kura Oncology Inc
5 own
15 watching
Current Price
$13.64
$-0.37
(-2.64%)
logo-kura
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
912.43M
52-Week High
52-Week High
19.93
52-Week Low
52-Week Low
10.41
Average Volume
Average Volume
1.13M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization912.43M
icon52-Week High19.93
icon52-Week Low10.41
iconAverage Volume1.13M
iconDividend Yield--
iconP/E Ratio--
What does the Kura Oncology Inc do?
Developing in-licensed protein inhibitors for solid tumors and blood cancers.
Read More
How much money does Kura Oncology Inc make?
News & Events about Kura Oncology Inc.
Globe Newswire
1month ago
30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML Low frequency of differentiation syndrome, including 5% rate (1/20) of Grade 3 among NPM1-mutant patients treated at 600 mg 600 mg determined as recommended Phase 2 dose for ziftomenib in NPM1-mutant AML following positive...
Zolmax
1month ago
Kura Oncology, Inc. (NASDAQ:KURA Get Rating) was the recipient of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 6,980,000 shares, an increase of 11.0% from the October 31st total of 6,290,000 shares. Approximately 10....
Globe Newswire
1month ago
In-person event and live webcast to follow oral presentation of data from KOMET-001 at ASH in New OrleansSAN DIEGO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the ...
Globe Newswire
2 months ago
SAN DIEGO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is ...
Ticker Report
2 months ago
Kura Oncology, Inc. (NASDAQ:KURA Get Rating) Analysts at Wedbush lowered their FY2025 EPS estimates for Kura Oncology in a note issued to investors on Thursday, November 3rd. Wedbush analyst R. Driscoll now anticipates that the company will earn $2.40 per share for the year, down ...
Frequently Asked Questions
Frequently Asked Questions
What is Kura Oncology Inc share price today?
plus_minus_icon
Can Indians buy Kura Oncology Inc shares?
plus_minus_icon
How can I buy Kura Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Kura Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Kura Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Kura Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Kura Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Kura Oncology Inc?
plus_minus_icon
What percentage is Kura Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Kura Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$13.64
$-0.37
(-2.64%)
logo-kura
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00